medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2011, Number 2

<< Back Next >>

Arch Neurocien 2011; 16 (2)

Clinical and demographic features of Parkinson’s disease from a tertiary referral center

Rodríguez-Violante M, Villar-Velarde A, Valencia-Ramos C, Cervantes-Arriaga A

Language: Spanish
References: 20
Page: 64-68
PDF size: 152.64 Kb.


ABSTRACT

Parkinson’s disease is one of the most frequent neurodegenerative disorders. Mexico currently lacks reliable epidemiological studies regarding this disease. Objective: to describe the prevalence and associations of the demographic, clinical and theraputhic features of Parkinson’s disease patients attending to the National Institute of Neurology and Neurosurgey in Mexico City in order to assess external validity. Patients and methods: we conducted an analytic cross-sectional study of all cases seen at the Abnormal Movement betwewn june 2007 and july 2009. Results: a total of 402 clinical files were reviewed from which 212 corresponded to Parkinson’s disease. Mean age was 63.1±11.4 years, 93% had mild to moderate disease, 70% were on levodopa preparations and 95% has at least one non-motor dysfunction symptom. Mean age of disease onset was around 3 years lower compared to other studies with men having an earlier onset (54.5 vs 59.9 years). Conclusions: with the only exception of age of disease onset, all other features of our hospital-based population are similar and therefore comparable with international population-based studies. Since actual epidemiologic data of Parkinson’s disease in Mexico is still missing this study may provide a broad picture of the current state of the disease in the country.


REFERENCES

  1. Weintraub D, Comella CL, Horn S. Parkinson’s disease Part 1. Pathophysiology, symptoms, burden and assessment. Am J Manag Care 2008; 14 (Suppl 2):S40-8.

  2. De Rijk MC, Launer LJ, Berger K, Breteler MM, Baldereschi. Prevalence of Parkinson’s disease in Europe: A collaborative study of population-based cohorts. Neurologic diseases in the elderly research group. Neurology 2000;54:S21-3.

  3. Belin AC, Westerlund M. Parkinson’s disease: a genetic perspective. FEBS J 2008; 275:1377-83.

  4. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology 2001; 57:1497-9.

  5. O’Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira- Moriyama L, Lees AJ. Nonmotor symptoms as presenting complaints in Parkinson’s disease: A clinicopathological study. Mov Disord 2007; 23: 101-6.

  6. Gulati A, Forbes A, Stegie F, Kelly L, Clough C, Chaudhauri KR. A clinical observational study of the pattern and ocurrence of nonmotor symproms in Parkinson’s disease ranging from early to advanced disease. Mov Disord 2004; 19(suppl9):S406.

  7. Jankovic J, Aguilar LG. Current approaches to the treatment of Parkinson’s disease. Neuropsychiatr Dis Treat 2008; 4:743-57.

  8. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988; 51:745-52.

  9. Instituto Nacional de Estadística, Geografía e Informática. Delimitación de las zonas metropolitanas de México 2005. INEGI. México, 2007.

  10. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17:427-42.

  11. Chaudhuri KR, Martínez-Martin P, Schapira AHV, Stocchi F, Sethi K. International multicenter pilot study of the first compre-hensive slef-completed nonmotor symptoms questionnaire for Parkinson ´s disease: The NMSQuest Study. Mov Disord 2006; 7: 916-23.

  12. Cervantes-Arriaga A, Rodríguez-Violante M, Villar-Velarde A, Corona T. Cálculo de unidades de equivalencia de levodopa en enfermedad de Parkinson. Arch Neurocien (Mex) 2009;14:116-9.

  13. Rybicki BA, Johnson CC, Gorell JM. Demographic differences in referral rates to neurologists of patients with suspected Parkinson’s disease: Implications for Case-Control Study design. Neuroepidemiology 1995; 14:72-81.

  14. Twelves D, Perkins KS, Co unsell C. Systematic review of incidence studies of Parkinson’s disease. Mov Disord 2003;18:19-31.

  15. Grosset D, Antonini A, Canesi M, Pezzoli G, Lees A, Shaw K, et al. Adherence to antiparkinson medication in a multicenter european study. Mov Disord 2009; 24:826-32.

  16. SwarzTrauber K, Koudelka C, Brodsky MA. Initial pharmacotherapy in a population of veterans with Parkinson disease. Neurology 2006; 66:1425-6.

  17. Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson’s disease. CNS Drugs 200; 21:677-92.

  18. Merello M. Non-motor disorders in Parkinson’s disease. Rev Neurol 2008; 47(5):261-70.

  19. Richard IH, Kurlan R. A survey of antidepressant drug use in Parkinson’s disease. Parkinson Study Group. Neurology 1997; 49:1168-70.

  20. Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S, et al. Depression rating scales in Parkinson’s disease: critique and recommendations. Mov Disord 2007; 22: 1077-92.




2020     |     www.medigraphic.com